Literature DB >> 21157151

[Evaluation of the performance of the MicroScan Pos Breakpoint Combo Panel Type 28 for susceptibility testing of Staphylococcus aureus: low-range minimum inhibitory concentration of vancomycin, cefoxitin screening, and inducible clindamycin resistance detection].

Misuk Ji1, Miyoung Lee, Sinae Noh, Mi-Na Kim.   

Abstract

BACKGROUND: Susceptibility testing of Staphylococcus aureus often requires cumbersome supplementary tests. MicroScan Pos Breakpoint Combo Panel Type 28 (PBC28) (Siemens, USA) includes cefoxitin screening to detect methicillin-resistant Staphylococcus aureus (MRSA), inducible clindamycin resistance detection (ICD), and determination of low-range minimum inhibitory concentration of vancomycin (0.5-16 µg/mL). The purpose of this study was to evaluate the performance of PBC28 in comparison with that of Pos Combo Type 1A (PC1A) (Siemens).
METHODS: From December 2009 to March 2010, 500 non-duplicate clinical isolates of S. aureus were tested with PC1A and PBC28. Categorical agreements (CA) between the interpretations of the 2 panels were estimated. The presence of the mecA gene was determined by PCR, and double-disk diffusion test (D-test) was performed on the isolates resistant to erythromycin but susceptible or intermediately resistant to clindamycin. Ninety-six isolates representing various vancomycin minimum inhibitory concentrations (MICs) were tested in parallel with repeat PBC28, broth macrodilution, and epsilometer test (E test).
RESULTS: The CA was 99.3% with a very major error (VME) of 0.2%, major error (ME) of 0.1%, and minor error (mE) of 0.4% in total. PBC28 showed 100% CA for 1 isolate with vancomycin MIC of 4 µg/mL and 35 isolates (7.0%) with MIC of 2 µg/mL. However, only 15, 27, and 35 isolates with vancomycin MIC of 2 µg/mL showed 100% CA in repeat PBC28, broth macrodilution, and E test, respectively. PC1A and PBC28 detected all 314 mecA-positive isolates. Among the 63 isolates tested with the D-test, 58 (92.1%) were positive, and the results were 100% concordant with those of ICD.
CONCLUSIONS: PBC28 can be appropriate susceptibility testing of S. aureus, including MRSA detection and ICD. However, the lower-range vancomycin MIC test was not reproducible enough to reliably differentiate MIC of 2 µg/mL from MIC ≤ 1 µg/mL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21157151     DOI: 10.3343/kjlm.2010.30.6.637

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


  3 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.

Authors:  Misuk Ji; Hyun-Ki Kim; Soo-Kyung Kim; Woochang Lee; Heungsup Sung; Sail Chun; Mi-Na Kim; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2015-10-26       Impact factor: 2.352

3.  Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  So-Youn Park; In-Hwan Oh; Hee-Joo Lee; Chun-Gyoo Ihm; Jun Seong Son; Mi Suk Lee; Mi-Na Kim
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.